Prurigo Nodularis: Review and Emerging Treatments

Maria Leis, BA; Patrick Fleming, MD, FRCPC; Charles W. Lynde, MD, FRCPC

Disclosures

Skin Therapy Letter. 2021;26(3):5-8. 

In This Article

Abstract and Introduction

Abstract

Prurigo nodularis (PN) is a chronic, recalcitrant inflammatory skin condition characterized by the presence of pruritic nodules. The exact pathogenesis of the disease is unknown, although immune and neural dysregulation are indicated in driving the itch-scratch cycle. Specifically, interleukin-4 and interleukin-31 pathways have been recently implicated in transmission of the pruritic sensation. There are currently no US FDA-approved targeted therapies for the treatment of PN. This article aims to review our present understanding of the disease pathogenesis and treatments, with a focus on emerging therapeutics. Specifically, this article explores the developing use of monoclonal antibodies nemolizumab and dupilumab, opioid receptor modulation and cannabinoids as potential treatments for PN.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....